This editorial refers to 'Angiographic late lumen loss revisited: impact on long-term target lesion revascularization' † ,
Implantation of coronary stents has become one of the most frequently performed interventional medical procedures, not least because its efficacy was substantially improved by the introduction of drug eluting stents (DES). 1 Target lesion revascularization (TLR), defined as a repeat intervention (i.e. percutaneous coronary intervention or coronary artery bypass graft surgery) due to restenosis within the stent (or its edge), has been used as the most common clinical endpoint of stent efficacy. Current metallic DES technology has demonstrated an outstanding reduction of TLR compared with bare metal stents (3 vs. 12%, number needed to treat 10). 2 The low incidence of TLR requires a large sample size to secure sufficient statistical power for the evaluation of new devices (i.e. to prove noninferiority compared to current standard devices). For this reason, several continuous angiographic measures obtained by quantitative coronary angiography analysis (QCA) such as minimal lumen diameter (MLD), diameter stenosis (DS), and late lumen loss (LLL) have been investigated as a surrogate marker of TLR. 3, 4 LLL, defined as MLD at post-procedure minus MLD at follow-up, has a particular ability to quantify the degree of neointimal hyperplasia independent of procedural variables (i.e. reference vessel diameter and residual stenosis) (Take home figure) . One-quarter of a century ago, LLL was reported by Dr Kuntz to evaluate the efficacy of balloon angioplasty and metallic stents. 5 Since then, LLL has been studied intensively for bare metal stents and first-generation DES, and has unquestionably achieved a gold standard status for assessing metallic stent efficacy. 3, 4 However, the prognostic value of LLL obtained by serial angiography for predicting repeat interventions has not been evaluated in the era of contemporary DES, representing a relevant gap in the field of interventional vascular medicine. In this issue of the European Heart Journal, Asano et al. this study lies in the derivation of the 0.50 mm threshold as a reasonably good independent marker for predicting future TLR in the era of new-generation DES. These findings are best summarized in Figure 1 of the author's article. Several limitations should be noted in the current study. First, both patient-and study-level analysis included a notable proportion of first-generation DES (1533/2426 patients), which are irrelevant for current practice. Second, analysis according to stent diameter, reportedly a strong confounding factor of TLR, was not conducted. Third, some TLRs were unavoidably driven by the occulo-stenotic reflex during follow-up angiography and may not have been based on objective criteria of ischaemia, despite independent event adjudication and application of the universal definition. Reassuringly, the predictive value of a > 0.50 mm LLL remained robust following a sensitivity analysis excluding TLRs that were eventually related to the routine angiographic followup. Finally, one should be aware about the selected population, in which serial angiography was performed.
LLL has several advantages as a study endpoint in patients treated with metallic DES: (i) it is a highly reproducible measure that can be assessed by any QCA-trained person; (ii) the basis is angiography and therefore the LLL data are available even in patients presenting with unplanned revascularization procedures [i.e. in difference to endpoints based on intracoronary imaging that is not (yet) broadly available]; (iii) it is a strong surrogate marker of TLR, as again shown in this analysis; and (iv) it is comparable parameter across trials. Notwithstanding these advantages, some limitations apply when considering the applicability of LLL.
Regarding its clinical applicability, LLL requires follow-up angiography, which is rarely performed in daily clinical practice. Coronary computed tomography angiography (CCTA) could represent a less cost-intensive and non-invasive alternative to follow-up angiography. Detailed quantitative assessment of the neointimal thickness represents a major unresolved technical challenge due to blooming artefacts of metallic struts (Take home figure) . Whether an invasive (or, in Take home figure Late lumen loss is an efficacy measure based on the minimal lumen diameter assessed by serial coronary angiography.
Optical coherence tomography is a high-resolution imaging technique that provides microscopic information on the stent and adjacent neointima, potentially useful to assess surrogates of device safety. Coronary computed tomography angiography is an attractive alternative to invasive angiography, yet current technical limitations do not allow precise neointimal assessment, as shown. (Coronary computed tomography angiography images were kindly provided by Dr C. Gräni, Bern University Hospital). the future, non-invasive) physiological assessment by fractional flow reserve (FFR) at follow-up angiography represents an alternative with better prediction of TLR remains to be investigated. Certainly, physiological parameters (i.e. FFR) also depend on segments proximal and distal to the stent attenuating the relationship with a specific device type.
The main application of LLL is limited to regulatory use (i.e. device approval) and comparative analyses. The European Society of Cardiology/European Association of Percutaneous Cardiovascular Interventions task force document recommends LLL of 0.34 mm (derived from upper the 95th percentile of nomogram for LLL of new-generation DES) for sample size calculation of trials using objective performance criteria.
2 Against this proposed cut-off, Asano et al.
consider replacing this threshold with the newly derived 0.50 mm cut-off. Approval trials usually include very low-risk lesions and introducing a LLL of 0.5 mm (i.e. what could almost be expected from a BMS device) as a new threshold in such a population may translate into unexpected high incidence of TLR following expansion to more complex settings. LLL is a solid marker for stent efficacy, but is unable to identify lesions at a potential risk for stent thrombosis. LLL is derived from one single cross-section at the position of the MLD at baseline and follow-up, and the remaining parts are disregarded, despite the presence of potentially relevant findings (e.g. positive remodelling). Angiography, as opposed to intracoronary optical coherence tomography (OCT), is unable to delineate strut-level abnormalities such as large zones of malapposition, uncovered struts, or neoatherosclerosis, findings that were reportedly associated with stent thrombosis and therefore merit consideration when assessing the potential safety of stents. Serial intracoronary imaging, and particularly OCT, has the potential to become an established surrogate of safety; however, the clinical implications of unfavourable OCT findings require further validation in large prospective studies.
Of note, care should be taken when interpreting angiographic results of bioresorbable scaffolds (BRS). BRS have greater residual stenosis at baseline (which does not find expression in the LLL), and LLL may not only be related to neointimal hyperplasia but importantly to mechanical properties such as low tensile strength and strut absorption. This stands in contrast with metallic stents, in which these factors are negligible. LLL results obtained from BRS are less reliable and absolutely mandate the addition of serial intracoronary imaging to enhance the understanding of mechanisms contributing to lumen changes.
Collectively, LLL is a well-established and robust indicator of metallic DES efficacy, and for many reasons, we will continue to refer to this parameter. Intracoronary imaging and potentially CCTA may supplement the limitations of LLL, and facilitate a more comprehensive assessment of devices in studies and clinical routine. 7 More widespread use (intracoronary imaging) and technical improvements (CCTA) are conditions sine qua non to make this happen.
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